Skip to Content

Table 51: Antiglaucoma Agents - Ophthalmic


A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z


Drug Category: Ophthalmic

Medication Class/Individual Agents: Antiglaucoma Agents

I. Prior-Authorization Requirements

 Antiglaucoma Agents: Ophthalmic – Alpha-Adrenergic Agents

Clinical Notes

Drug Details

Drug Generic Name

Drug Brand Name

PA
Status

Drug
Notes

apraclonidine Iopidine test   # , M90
brimonidine 0.1%, 0.15% eye drops Alphagan P test   BP, M90
brimonidine 0.2% eye drops test   M90

Please note: In the case where the prior authorization (PA) status column indicates PA, both the brand and generic (if available) require PA. Typically, the generic is preferred when available unless the brand-name drug appears on the MassHealth Brand Name Preferred Over Generic Drug List. In general, when requesting the non-preferred version, whether the brand or generic, the prescriber must provide medical records documenting an inadequate response or adverse reaction to the preferred version, in addition to satisfying the criteria for the drug itself.

  • Patients diagnosed with ocular hypertension or suspected open-angle glaucoma should be offered medication based on the risk factors for developing primary open-angle glaucoma such as high intraocular pressure (IOP), type 2 diabetes mellitus, and older age.1
  • Ophthalmic prostaglandin analogues are often considered first-line. If target IOP has not been achieved, switching to an alternative medication or adding additional medication (e.g., ophthalmic beta-blockers, alpha-2 adrenergic agonists, carbonic anhydrase inhibitors, parasympathomimetics) is recommended.2

Gedde SJ, Lind JT, Wright MM, Chen PP, Muir KW, Vinod K, et al. Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern Guidelines. Ophthalmology. 2020 Nov; 128(1):P151-192.

2 Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern Guidelines. Ophthalmology. 2020 Nov;128(1):P71-P150.

 

 Antiglaucoma Agents: Ophthalmic – Beta-Adrenergic Agents

Drug Details

Drug Generic Name

Drug Brand Name

PA
Status

Drug
Notes

betaxolol 0.25% Betoptic S test  
betaxolol 0.5% test   M90
carteolol test   M90
levobunolol test   M90
timolol ophthalmic gel forming solution Timoptic-XE PA   M90
timolol ophthalmic unit dose solution Timoptic Ocudose PA   BP, A90
timolol-Betimol Betimol PA  
timolol-Istalol Istalol test   BP, M90
timolol-Timoptic Timoptic test   # , M90

 Antiglaucoma Agents: Ophthalmic – Carbonic Anhydrase Inhibitors

Drug Details

Drug Generic Name

Drug Brand Name

PA
Status

Drug
Notes

brinzolamide Azopt test   BP, M90
dorzolamide Trusopt test   # , M90

 Antiglaucoma Agents: Ophthalmic – Combination Products

Drug Details

Drug Generic Name

Drug Brand Name

PA
Status

Drug
Notes

brimonidine / timolol, ophthalmic Combigan test   BP, M90
brinzolamide / brimonidine Simbrinza test  
dorzolamide / timolol Cosopt test   # , M90
dorzolamide / timolol, preservative free Cosopt PF PA   BP, M90
netarsudil / latanoprost Rocklatan PA  

 Antiglaucoma Agents: Ophthalmic – Miotics

Drug Details

Drug Generic Name

Drug Brand Name

PA
Status

Drug
Notes

acetylcholine chloride Miochol-E test  
carbachol 0.01% Miostat test  
pilocarpine 1%, 2%, 4% ophthalmic solution Isopto Carpine test   # , M90

 Antiglaucoma Agents: Ophthalmic – Prostaglandins

Drug Details

Drug Generic Name

Drug Brand Name

PA
Status

Drug
Notes

bimatoprost 0.01% ophthalmic solution Lumigan test  
bimatoprost 0.03% ophthalmic solution PA   M90
bimatoprost implant Durysta PA  
latanoprost emulsion Xelpros PA  
latanoprost solution Xalatan test   # , M90
latanoprostene Vyzulta PA  
tafluprost Zioptan PA  
travoprost 0.004% eye drop Travatan Z test   BP, M90

 Antiglaucoma Agents: Ophthalmic – Rho Kinase Inhibitor

Drug Details

Drug Generic Name

Drug Brand Name

PA
Status

Drug
Notes

netarsudil Rhopressa PA  
Table Footnotes
# This designates a brand-name drug with FDA “A”-rated generic equivalents. Prior authorization is required for the brand, unless a particular form of that drug (for example, tablet, capsule, or liquid) does not have an FDA “A”-rated generic equivalent.
 
BP Brand Preferred over generic equivalents. In general, MassHealth requires a trial of the preferred drug or clinical rationale for prescribing the non-preferred drug generic equivalent.
 
A90 Allowable 90-day supply. Dispensing in up to a 90-day supply is allowed. May not include all strengths or formulations. Quantity limits and other restrictions may apply.
 
M90 Effective 12/19/22, mandatory 90-day supply. After dispensing up to a 30-day supply initial fill, dispensing in a 90-day supply is required. May not include all strengths or formulations. Quantity limits and other restrictions may also apply. Prior to 12/19/22, allowable 90-day supply and dispensing in up to a 90-day supply is allowed.
 

II. Therapeutic Uses

FDA-approved, for example:

  • Ocular hypertension
  • Open-angle glaucoma

Note: The above list may not include all FDA-approved indications.

Back to top


III.  Evaluation Criteria for Approval

Please note: In the case where the prior authorization (PA) status column indicates PA, both the brand and generic (if available) require PA. Typically, the generic is preferred when available unless the brand-name drug appears on the MassHealth Brand Name Preferred Over Generic Drug List. In general, when requesting the non-preferred version, whether the brand or generic, the prescriber must provide medical records documenting an inadequate response or adverse reaction to the preferred version, in addition to satisfying the criteria for the drug itself.

  • All PA requests must include clinical diagnosis, drug name, dose, and frequency.
  • Dispensing in a 90-day supply of medication may be mandated or allowable for agents in this therapeutic class (designated by M90 or A90, respectively, in the Drug Notes section above). Applicable quantity limits are described below as units per day, per month, per 28 days, or as clinically appropriate, and may be extrapolated for fills of longer day supply. 
  • A preferred drug may be designated for this therapeutic class. In general, MassHealth requires a trial of the preferred drug or clinical rationale for prescribing a non-preferred drug within a therapeutic class. Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at www.mass.gov/druglist.
  • For recertification requests, approval may require submission of additional documentation including, but not limited to, documentation of: some or all criteria for the original approval; response to therapy; clinical rationale for continuation of use; status of member’s condition; appropriate diagnosis; appropriate age; appropriate dose, frequency, and duration of use for requested medication; complete treatment plan; current laboratory values; and member’s current weight.
  • Additional criteria may apply, depending upon the member’s condition and requested medication (see below).

 

Betimol

  • Documentation of the following is required:
    • appropriate diagnosis; and
    • inadequate response or adverse reaction to an ophthalmic timolol product that does not require a prior authorization.

SmartPA: Claims for Betimol will usually process at the pharmacy without a PA request if the member has a history of paid MassHealth pharmacy claims for an ophthalmic timolol product that does not require a prior authorization.†

     

bimatoprost 0.03% ophthalmic solution

  • Documentation of the following is required:
    • appropriate diagnosis; and
    • inadequate response or adverse reaction to Lumigan.

      

dorzolamide/timolol preservative free and Xelpros

  • Documentation of the following is required:
    • appropriate diagnosis; and
    • sensitivity to benzalkonium chloride or any other preservative used in ophthalmic preparations.

    

Durysta

  • Documentation of the following is required:
    • appropriate diagnosis; and
    • one of the following:
      • inadequate response or adverse reaction to Lumigan; or
      • medical necessity for an implantable formulation instead of eye drops (e.g., limited dexterity, visual impairment, intellectual disability, comorbidities, etc.); and
    • affected eye has not previously been treated with Durysta.

    

Rhopressa

  • Documentation of the following is required:
    • appropriate diagnosis; and
    • member is ≥ 18 years old; and
    • one of the following:
      • inadequate response to combination therapy with a prostaglandin analog and an ophthalmic beta-blocker; or
      • contraindication or adverse reaction to prostaglandin analogs and ophthalmic beta-blockers; or
      • both of the following:
        • contraindication to ophthalmic beta-blockers; and
        • inadequate response or adverse reaction to a prostaglandin analog in combination with one of the following: ophthalmic alpha-2 adrenergic agonist, parasympathomimetic, carbonic anhydrase inhibitor; or
      • both of the following:
        • contraindication to prostaglandin analogs; and
        • inadequate response or adverse reaction to an ophthalmic beta-blocker in combination with one of the following: ophthalmic alpha-2 adrenergic agonist, parasympathomimetic, carbonic anhydrase inhibitor.

 

Rocklatan

  • Documentation of the following is required:
    • appropriate diagnosis; and
    • member is ≥ 18 years old; and
    • one of the following:
      • inadequate response to combination therapy with a prostaglandin analog and an ophthalmic beta-blocker; or
      • both of the following:
        • contraindication to ophthalmic beta-blockers; and
        • inadequate response or adverse reaction to a prostaglandin analog in combination with one of the following: ophthalmic alpha-2 adrenergic agonist, parasympathomimetic, carbonic anhydrase inhibitor.

    

timolol ophthalmic gel forming solution

  • Documentation of the following is required:
    • appropriate diagnosis; and
    • inadequate response or adverse reaction to an ophthalmic timolol-containing product.

SmartPA: Claims for timolol ophthalmic gel forming solution will usually process at the pharmacy without a PA request if the member has a history of paid MassHealth pharmacy claims for an ophthalmic timolol-containing product.†

 

timolol ophthalmic unit dose solution

  • Documentation of the following is required:
    • appropriate diagnosis; and
    • one of the following:
      • inadequate response or adverse reaction to an ophthalmic timolol product that does not require a prior authorization; or 
      • sensitivity to benzalkonium chloride.

SmartPA: Claims for timolol ophthalmic unit dose solution will usually process at the pharmacy without a PA request if the member has a history of paid MassHealth pharmacy claims for an ophthalmic timolol product that does not require a prior authorization.†

     

Vyzulta

  • Documentation of the following is required:
    • appropriate diagnosis; and
    • member is ≥ 17 years old; and
    • one of the following:
      • inadequate response to combination therapy with latanoprost solution and an ophthalmic beta-blocker; or
      • both of the following:
        • inadequate response to latanoprost solution; and
        • contraindication or adverse reaction to an ophthalmic beta-blocker.

     

Zioptan

  • Documentation of the following is required:
    • appropriate diagnosis; and
    • inadequate response, adverse reaction, or contraindication to Xelpros; and
    • one of the following:
      • inadequate response, adverse reaction or contraindication to latanoprost solution; or
      • sensitivity to benzalkonium chloride or any other preservative used in ophthalmic preparations.

SmartPA: Claims for Zioptan will usually process at the pharmacy without a PA request if the member has a history of paid MassHealth pharmacy claims for latanoprost solution and Xelpros.†


† Note: The decision on whether PA is required is based upon information available in the MassHealth medical claim and pharmacy claim databases. The MassHealth database contains member information exclusive to MassHealth, and no other health plans.


Original Effective Date: 11/2010

Last Revised Date: 09/2022


Clinical Criteria Main Page | Back to topPrevious  |  Next

Last updated 09/19/22

Feedback